上海交通大学学报(医学版) ›› 2022, Vol. 42 ›› Issue (12): 1745-1750.doi: 10.3969/j.issn.1674-8115.2022.12.013

• 综述 • 上一篇    

乳腺癌合并新型冠状病毒肺炎感染患者的抗肿瘤合理化诊疗方案探讨

张郁瑭1(), 金奕婕1, 张凤春2, 徐迎春1()   

  1. 1.上海交通大学医学院附属仁济医院肿瘤科,上海 200127
    2.上海交通大学医学院苏州九龙医院肿瘤科,苏州 215127
  • 收稿日期:2022-06-24 接受日期:2022-09-04 出版日期:2022-12-28 发布日期:2022-12-28
  • 通讯作者: 徐迎春 E-mail:553572892@qq.com;xiaoxu2384@163.com
  • 作者简介:张郁瑭(1999—),男,本科生;电子信箱:553572892@qq.com
  • 基金资助:
    国家自然科学基金(81301858);苏州市科技计划项目(SYS201404);江苏省自然科学基金(BK20181186)

Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19

ZHANG Yutang1(), JIN Yijie1, ZHANG Fengchun2, XU Yingchun1()   

  1. 1.Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215127, China
  • Received:2022-06-24 Accepted:2022-09-04 Online:2022-12-28 Published:2022-12-28
  • Contact: XU Yingchun E-mail:553572892@qq.com;xiaoxu2384@163.com
  • Supported by:
    National Natural Science Foundation of China(81301858);Suzhou Science and Technology Project(SYS201404);Natural Science Foundation of Jiangsu Province(BK20181186)

摘要:

新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)作为一种新发的急性呼吸道传染病,目前已成为全球性重大公共卫生事件。在COVID-19流行期间,与健康人群相比,癌症患者因基础免疫力较差、年龄较大等特点,感染COVID-19后发生其他系统并发症的风险更高。研究显示,在女性恶性肿瘤中,乳腺癌的发病率位居第一。该类患者合并COVID-19感染的预后更差,且因COVID-19感染而不得不推迟抗肿瘤治疗。目前,关于推迟治疗对乳腺癌患者生存期的影响尚不明确,是否应调整这部分患者的治疗方案也仍处于研究中。该文通过系统回顾现有临床研究结果、各学会指南及专家共识,对COVID-19疫情下乳腺癌治疗方案的选择及合理化调整进行综述,探讨COVID-19感染的乳腺癌患者的抗肿瘤治疗时机和合理可行的抗肿瘤治疗方式。

关键词: 乳腺癌, 新型冠状病毒肺炎, 手术, 放射治疗, 系统治疗

Abstract:

Coronavirus disease 2019 (COVID-19) has become a major global public health event as a new acute respiratory infectious disease. During the COVID-19 pandemic, compared with the healthy population, cancer patients had a higher risk of developing comorbidities of other systems, due to their bad poor immunity and older age. Research showed that breast cancer, as a malignant disease, had the highest disease incidence in female patients. Breast cancer patients with COVID-19 infection often have worse prognosis, and they have to postpone anti-tumor treatment due to COVID-19 infection. At present, the effect of delayed treatment on the survival rate of breast cancer patients is unclear, and whether the treatment plan of these patients should be adjusted is still being studied. Through the systematic review of existing clinical research studies, the guidelines of various societies and the expert consensus, this paper reviews the selection and rationalization of breast cancer treatment options under the COVID-19 epidemic, and discusses the opportunity and approaches of anti-tumor treatment for breast cancer patients infected with COVID-19.

Key words: breast cancer, coronavirus disease 2019 (COVID-19), surgery, radiotherapy, systemic therapy

中图分类号: